Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To Profit
Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Theravance Biopharma, Inc.'s (NASDAQ:TBPH) future prospects. Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The US$443m market-cap company's loss lessened since it announced a US$93m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$61m, as it approaches breakeven. Many investors are wondering about the rate at which Theravance Biopharma will turn a profit, with the big question being "when will the company breakeven?" We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
由於該業務可能處於重要的里程碑,我們認爲可以仔細研究Theravance Biopharma, Inc.”s(納斯達克股票代碼:TBPH)的未來前景。生物製藥公司Theravance Biopharma, Inc. 在美國和歐洲發現、開發和商業化呼吸道藥物。自宣佈全年虧損9300萬美元以來,這家市值爲4.43億美元的公司虧損有所減少,而在接近盈虧平衡之際,最近十二個月的虧損爲6100萬美元。許多投資者想知道Theravance Biopharma的盈利速度,最大的問題是 “公司何時會實現盈虧平衡?”我們簡要概述了行業分析師對該公司、盈虧平衡年份和隱含增長率的預期。
Theravance Biopharma is bordering on breakeven, according to the 4 American Pharmaceuticals analysts. They expect the company to post a final loss in 2025, before turning a profit of US$54m in 2026. The company is therefore projected to breakeven around 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 56% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
四位美國製藥分析師表示,Theravance Biopharma已接近盈虧平衡。他們預計,該公司將在2025年公佈最終虧損,然後在2026年實現5400萬美元的盈利。因此,預計該公司將在大約兩年後實現盈虧平衡。爲了在2026年之前達到盈虧平衡點,公司每年必須以多快的速度增長?從分析師的估計來看,事實證明,他們預計該公司平均同比增長56%,這表明分析師充滿信心。如果事實證明這個利率過於激進,該公司的盈利時間可能比分析師預測的要晚得多。
Given this is a high-level overview, we won't go into details of Theravance Biopharma's upcoming projects, though, keep in mind that by and large pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
鑑於這是一個高層次的概述,我們不會詳細介紹Theravance Biopharma即將推出的項目,但請記住,總的來說,藥品的現金流週期不規律,視產品開發階段而定。這意味着高增長率並不罕見,尤其是在公司目前處於投資期的情況下。
Before we wrap up, there's one aspect worth mentioning. Theravance Biopharma currently has no debt on its balance sheet, which is rare for a loss-making pharma, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
在我們總結之前,有一個方面值得一提。Theravance Biopharma目前的資產負債表上沒有債務,這對於虧損的製藥公司來說是罕見的,因爲相對於其股權,債務水平通常很高。這意味着該公司一直完全依靠股權投資運營,沒有債務負擔。這方面降低了投資這家虧損公司的風險。
Next Steps:
後續步驟:
This article is not intended to be a comprehensive analysis on Theravance Biopharma, so if you are interested in understanding the company at a deeper level, take a look at Theravance Biopharma's company page on Simply Wall St. We've also put together a list of essential factors you should further examine:
本文無意對Theravance Biopharma進行全面分析,因此,如果你有興趣更深入地了解該公司,可以看看Theravance Biopharma在Simply Wall St的公司頁面。我們還整理了一份你應該進一步研究的基本因素清單:
- Valuation: What is Theravance Biopharma worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Theravance Biopharma is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Theravance Biopharma's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Theravance Biopharma 今天的價值是多少?價格中是否已經考慮了未來的增長潛力?我們的免費研究報告中的內在價值信息圖有助於可視化Theravance Biopharma目前是否被市場定價錯誤。
- 管理團隊:一支經驗豐富的管理團隊掌舵增強了我們對業務的信心——看看誰是Theravance Biopharma董事會成員以及首席執行官的背景。
- 其他表現優異的股票:還有其他股票可以提供更好的前景並有良好的往績記錄嗎?在這裏瀏覽我們免費列出的這些優質股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。